Vistagen reported a net loss primarily driven by research and development expenses for its CNS pipeline, including Phase 3 trials for fasedienol. The company maintains a cash runway to support operations through upcoming clinical milestones, though it currently generates no product revenue.
Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update on its fasedienol Phase 3 development plan for social anxiety disorder. The company highlighted constructive FDA feedback regarding its clinical trial design and the appointment of Dr. Douglas J. Williamson to its Board of Directors. Vistagen also implemented cost-management initiatives to prioritize capital for its late-stage neuroscience programs.
Term
Q2 2027
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder”
Shawn Singh, President and Chief Executive Officer of Vistagen
“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
Shawn Singh, President and Chief Executive Officer of Vistagen
Vistagen announced a productive Type C meeting with the FDA regarding the Phase 3 development path for its lead candidate, fasedienol, in social anxiety disorder (SAD). The FDA provided constructive feedback on using the Liebowitz Social Anxiety Scale (LSAS) as a primary endpoint and recommended incorporating interim assessments to evaluate long-term functional improvement.
Vistagen Therapeutics implemented a 31% reduction in its workforce to reduce operating expenses and preserve capital for its Phase 3 development of fasedienol. The company expects to incur approximately $1.0 million in one-time severance and termination costs while realizing annual savings of approximately $3.2 million in salary and benefits.
Vistagen Therapeutics has amended and restated its Executive Severance Plan to expand the circumstances under which eligible employees, including executive officers, receive benefits. The new plan now provides cash severance and COBRA premiums for terminations without cause regardless of whether a change in control occurs, whereas the previous plan required a change in control event.
Vistagen Therapeutics filed a new corporate presentation dated September 2026 to be used for investor communications. The presentation highlights the company's focus on neurocircuitry-based therapies, specifically its pherine product candidates like fasedienol.
Vistagen presented positive exploratory data at Psych Congress 2026 showing that its Phase 3 candidate fasedienol (PH94B) demonstrated statistically significant improvements in anxiety symptoms for patients with very severe social anxiety disorder. The findings, derived from post-hoc and prespecified subpopulation analyses of the PALISADE-4 and Phase 2a RDS trials, suggest that fasedienol may provide rapid-onset relief and that a second dose could further improve anticipatory anxiety.
Vistagen announced preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study of fasedienol for social anxiety disorder. The data showed the nasal spray was well-tolerated over 12 months of as-needed use and demonstrated clinically relevant improvements in social anxiety symptoms on both clinician-administered and patient-reported scales. The company plans to meet with the FDA this quarter to discuss the regulatory path forward for a potential New Drug Application.